China National Pharmaceutical Group: Net profit is expected to grow by 76.8% to 1.14 billion yuan by 2025, with the sales scale of Guoda Pharmacy continuing to increase.

LightningPacketLoss · 2026-04-02T12:23:38+00:00

China National Pharmaceutical Group (Sinopharm) releases its 2025 annual report, with operating revenue of 73.42 billion yuan, down 1.3% year-on-year; net profit attributable to the parent company of 1.14 billion yuan, up 76.8% year-on-year. The company's business covers pharmaceutical distribution and Guoda Pharmacy retail. After optimizing distribution operations, the business remains stable, and social pharmacies have made significant progress in chronic disease management. Overall, the business structure has achieved steady growth.

LightningPacketLoss

2026-04-02 12:23:38

Abstract generation in progress

Recently, Sinopharm Concordant issued its 2025 annual report. The company’s operating revenue was 73.42 billion yuan, down 1.3% year over year; net profit attributable to shareholders was 1.14 billion yuan, up 76.8% year over year; and net profit attributable to shareholders after deducting non-recurring items was 1.10 billion yuan, up 88.5% year over year.

In its 2025 annual report, the company stated that its core business covers pharmaceutical distribution business mainly centered on the two Guangdong Guangxi regions, and nationwide retail pharmacy business mainly driven by Guoda Pharmacy. During the reporting period, in the distribution business segment, by optimizing resource allocation and product mix, the company actively expanded into the market. Operating conditions remained steady and improved, with the core main business enhancing quality and efficiency and upgrading its structure.

In the social pharmacy sector, Guoda Pharmacy’s sales scale continued to grow, with notable progress particularly in chronic disease management and member services. The company also continued to advance its investments in pharmaceutical industrial enterprises, including research and production in fields such as anti-infectives and respiratory system medications. Overall, during the reporting period, the company’s business structure and market layout achieved relatively steady growth.

(Sinopharm Concordant announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.